Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. (Q45198729)
Jump to navigation
Jump to search
scientific article published in December 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. |
scientific article published in December 2004 |
Statements
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays (English)
Louis J Lombardo
Francis Y Lee
Ping Chen
Derek Norris
Joel C Barrish
Kamelia Behnia
Stephen Castaneda
Lyndon A M Cornelius
Jagabandhu Das
Arthur M Doweyko
Craig Fairchild
Ivan Inigo
Kathy Johnston
Amrita Kamath
David Kan
Herbert Klei
Punit Marathe
Suhong Pang
Russell Peterson
Sidney Pitt
Gary L Schieven
Robert J Schmidt
John Tokarski
Mei-Li Wen
John Wityak
Robert M Borzilleri
1 December 2004